Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497326 | 0.80 | OPRM1 (0.54) | GRM2GRM3MEN1KMT2AEPHX1 | |
| SCHEMBL2730868 | 0.79 | ACHE (0.49) | KMT2AEPHX1CA2 | |
| SCHEMBL5493230 | 0.78 | DRD4 (0.50) | GRM2SIGMAR1KDM4EEPHX1 | |
| SCHEMBL15492796 | 0.76 | HTT (0.55) | MEN1KMT2AKDM4EALDH1A1EPHX1 | |
| SCHEMBL10433983 | 0.75 | KMT2A (0.57) | MEN1KMT2AKDM4EALDH1A1EPHX1 | |
| Hydrochloric Acid SCHEMBL10433976 | 0.74 | KMT2A (0.56) | MEN1KMT2AKDM4EALDH1A1EPHX1 | |
| SCHEMBL1006286 | 0.73 | SLC6A4 (0.54) | KMT2ACA2 | |
| SCHEMBL5497334 | 0.71 | GRM2 (0.43) | GRM2GRM3MEN1KMT2ATDP1 | |
| SCHEMBL8973459 | 0.68 | GRM2 (1.00) | GRM2GRM3 | |
| SCHEMBL8972992 | 0.68 | GRM2 (1.00) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262163-B2 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | MCLAUGHLIN MARK L (US) | 2004-03-25 | — | — | US | disclosed |
| US-6566334-B1 | For therapy of bacterial infection | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | VIP, MDK, HM13 | GRM2 4555/4885GRM3 4151/4885MEN1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.